BioVersys AG (XSWX:BIOV) ROE % Adjusted to Book Value: -13.96% (As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.00
View Full Analysis

What is BioVersys AG ROE % Adjusted to Book Value?

BioVersys AG XSWX:BIOV 4 ROE % Adjusted to Book Value is -13.96% as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's ROE % for the quarter that ended in Dec. 2025 was -33.37%. BioVersys AG's PB Ratio for the quarter that ended in Dec. 2025 was 2.39. BioVersys AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -13.96%.

BioVersys AG ROE % Adjusted to Book Value Related Terms

BioVersys AG ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BioVersys AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG ROE % Adjusted to Book Value Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
ROE % Adjusted to Book Value
0.00 -25.92

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value 0.00 0.00 -18.79 -13.96

XSWX:BIOV vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, BioVersys AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVersys AG ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BioVersys AG's ROE % Adjusted to Book Value falls into.


XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG ROE % Adjusted to Book Value Calculation

BioVersys AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-61.94% / 2.39
=-25.92%

BioVersys AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-33.37% / 2.39
=-13.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -13.96% mean?
BioVersys AG (XSWX:BIOV) has a ROE % Adjusted to Book Value of -13.96% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's ROE % Adjusted to Book Value too high?
BioVersys AG's current ROE % Adjusted to Book Value is -13.96%. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's ROE % Adjusted to Book Value compare to VRTX and REGN?
BioVersys AG's ROE % Adjusted to Book Value of -13.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioVersys AG and its competitors. BioVersys AG's current ROE % Adjusted to Book Value is -13.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current ROE % Adjusted to Book Value of -13.96%. The current ROE % Adjusted to Book Value is -13.96%. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current ROE % Adjusted to Book Value is -13.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.00
Price